DNA modifications and alzheimer’s disease

15Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Alzheimer’s disease (AD) is a complex neurodegenerative disease, affecting millions of people worldwide. While a number of studies have focused on identifying genetic variants that contribute to the development and progression of late-onset AD, the majority of these only have a relatively small effect size. There are also a number of other risk factors, for example, age, gender, and other comorbidities; however, how these influence disease risk is not known. Therefore, in recent years, research has begun to investigate epigenetic mechanisms for a potential role in disease etiology. In this chapter, we discuss the current state of play for research into DNA modifications in AD, the most well studied being 5-methylcytosine (5-mC). We describe the earlier studies of candidate genes and global measures of DNA modifications in human AD samples, in addition to studies in mouse models of AD. We focus on recent epigenome-wide association studies (EWAS) in human AD, using microarray technology, examining a number of key study design issues pertinent to such studies. Finally, we discuss how new technological advances could further progress the research field.

Cite

CITATION STYLE

APA

Smith, R. G., & Lunnon, K. (2017). DNA modifications and alzheimer’s disease. In Advances in Experimental Medicine and Biology (Vol. 978, pp. 303–319). Springer New York LLC. https://doi.org/10.1007/978-3-319-53889-1_16

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free